StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock analysis

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 4/30
$1.93−0.01 (-0.52%)

Close on Nov 11, 2026Market cap $375.42MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value1Growth0Performance1Health2Dividend0

Weak4 of 30 checks passed

Altimmune passes 4 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
0/6
Past performance
1/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 7.3% of shareholders' equity, under the 40% we consider low.

  • P/B below the industry

    Altimmune's price-to-book of 0.79 is below the Drugs median of 2.29.

  • Return on equity above the industry

    Altimmune's return on equity of -28.9% is above the Drugs median of -58.9%.

  • Short-term assets cover short-term debts

    Current assets are 26.78 times current liabilities.

What to watch

  • Return on equity under 15%

    Return on equity was -28.9% over the last twelve months and averaged -49.4% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -90.4%, below the 10% that usually covers the cost of capital.

  • Interest not well covered

    Operating income covers interest expense -28.3 times; we look for at least 5.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -220% of total debt; we look for at least 20%.

Valuation1/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    Altimmune's price-to-book of 0.79 is below the Drugs median of 2.29.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -28.9% over the last twelve months and averaged -49.4% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -90.4%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Altimmune's return on equity of -28.9% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health2/6

  • Low debt

    Debt is 7.3% of shareholders' equity, under the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 0.8% five years ago to 7.3%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -220% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -28.3 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 26.78 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.51; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Altimmune has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Altimmune. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 2.2
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$8.42M
Value traded per 1% price move
$3.57M

Downside

High risk

Typical loss in a bad month
31.2%
Volatility (annualized)
70%
Sharpe ratio, 1 year
-0.85
Beta to the S&P 500 (5Y)
1.10

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Operating margin

-230461.0%−229791.5 pts over 5 years

Net margin

-214861.0%−214261.8 pts over 5 years

See a number that looks wrong?